ROBOSENSE
29.8.2022 16:49:11 CEST | Business Wire | Press release
RoboSense, a world-leading provider of Smart LiDAR Sensor Systems today announced that it will provide LiDAR for Great Wall Motor WEY Mocha DHT-PHEV LiDAR Edition. On the same day, WEY Mocha DHT-PHEV LiDAR Edition was officially launched at the 25th Chengdu International Auto Show.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220826005302/en/
Great Wall Motor WEY Mocha SUV equipped with two RS-LiDAR-M1
Based on WEY’s Mocha DHT-PHEV LiDAR Edition, RoboSense, together with Haomo.AI and Qualcomm, jointly created the urban driving assistance solution NOH for WEY. In particular, RoboSense second-generation smart solid-state LiDAR (RS-LiDAR-M1) are deployed under the headlights on both sides of the vehicle, one on each side, which give Mocha DHT-PHEV accurate perception capabilities and provide an extra level of perception safety redundancy. Adopting the perception-focused technology path, Mocha DHT-PHEV can perceive, think and make decisions like a human being, and full coverage of China’s high-speed and urban road commuting scenes is realized - smarter intelligence for driving assistance; safer and cozier driving experience for consumers.
With the large-scale application of intelligent driving technologies, the increasingly more complex application scenarios put higher automotive-grade reliability requirements for LiDAR on the front side of the vehicle body. Mocha DHT-PHEV’s intelligent driving application scenarios cover all kinds of high-speed and urban road conditions. Complex road conditions will bring various challenges to LiDAR.
RS-LiDAR-M1 adopts highly-integrated design, and has passed a series of reliability tests in accordance with strict passenger vehicle standards, including mechanical shock, random vibration, high-pressure water impact, high and low temperature operation, high and low temperature damp heat, solar radiation, EMC, chemical anti-corrosion, salt spray and other tests. It fully meets the safety, reliability and service life requirements of Mocha DHT-PHEV in complex high-speed and urban road scenarios.
Meanwhile, thanks to the revolutionary 2D MEMS LiDAR technology platform, M1’s unique smart “GAZE” function can dynamically switch scanning modes according to different scenarios such as high-speed railways and urban areas, giving urban NOH ADAS solution the differentiated scenario perception capability, safeguarding and ensuring the smart driving experience of Mocha DHT-PHEV LiDAR Edition.
With its leading technological strengths in the field of LiDAR, RoboSense has obtained design wins for more than 50 models from companies including Great Wall Motor, BYD, FAW Hongqi, GAC AION, ZEEKR, WM Motor, Lotus Cars, Lucid Motors, Inceptio Technology and Zhito Technology. RoboSense will always pursue technological innovation and keep promoting the large-scale production of smart vehicles.
About RoboSense
RoboSense is a world-leading provider of Smart LiDAR Sensor Systems. With a complete portfolio of LiDAR sensors, AI perception and IC chipsets, RoboSense transforms conventional 3D LiDAR sensors with comprehensive data analysis and interpretation systems. Its mission is to innovate outstanding hardware and AI capabilities to create smart solutions that enable robots, including autonomous vehicles, to have perception capabilities superior to humans.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220826005302/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom